Shuttle Pharmaceuticals Holdings, Inc. 8-K

What Happened
Shuttle Pharmaceuticals Holdings, Inc. filed an 8‑K (reflecting a Form S‑1 filed Feb 11, 2026) disclosing preliminary unaudited financial results for the year ended December 31, 2025. The company reported no revenue for 2025 and expects a net loss in a range of $10,862,448 to $12,083,466, compared with an actual 2024 net loss of $9,144,797. These figures are preliminary, unaudited and subject to change; the company’s auditors have not reviewed them.

Key Details

• Net loss (preliminary, FY2025): $10.86M to $12.08M vs FY2024 actual $9.14M. Revenue: $0 for both years.
• Operating expenses (FY2025 estimates): R&D $3.42M–$3.85M (vs $3.62M in 2024); G&A $5.23M–$5.78M (vs $1.39M in 2024) — increase largely due to ~$3.6M in investor-relations advertising; Legal & professional $2.08M–$2.30M (vs $2.68M in 2024).
• Balance sheet highlights (Dec 31, 2025 estimates): Current assets ≈ $502,744; current liabilities ≈ $1.19M–$1.31M → working capital deficit ≈ $0.7M–$0.8M (vs $0.7M working capital at 12/31/2024).
• Acquisition and liabilities: Intangible assets, net ≈ $9.814M from the Molecule.ai asset acquisition; contingent consideration ≈ $2.0M and consideration payable ≈ $4.436M. All previously outstanding notes and related interest were paid or converted in 2025, reducing note liabilities to $0.

Why It Matters
For investors, the key takeaways are higher cash burn in 2025 driven by increased G&A (notably investor‑relations spending), a material working capital deficit, and new intangible and contingent liabilities tied to the Molecule.ai acquisition. The filing also warns these are preliminary, unaudited results and that the company’s near‑term viability depends on raising additional equity or debt financing. Investors should treat these numbers as estimates until Shuttle releases its final, audited FY2025 results.